On 30 June 2025, BerGenBio ASA (“BerGenBio”) and Oncoinvent ASA (“Oncoinvent”) announced that they have entered into a merger agreement to combine the two companies through a statutory merger, where BerGenBio will be the acquiring entity. Following the merger, the combined company shall carry out a NOK 130m fully underwritten rights issue.
ABG Sundal Collier acted as exclusive financial advisor to Oncoinvent in connection with the merger and is acting as joint lead manager and joint bookrunner in connection with the NOK 130m fully underwritten rights issue.
The merger will add approximately NOK 45 million in cash to fund Oncoinvent’s clinical development plan, and together with the proceeds from the rights issue, fund the company through several milestones. Moreover, the combination will substantially broaden the shareholder base, improving liquidity in the share and enable an uplisting from Euronext Growth Oslo, subject to approval by the Oslo Stock Exchange.
The merger is supported by BerGenBio’s largest shareholder Meteva AS and Oncoinvent’s largest shareholders, Hadean Ventures and Linc AB, all of whom have entered into voting undertakings to vote in favour of the merger and lock-up commitments for a period of six months following this announcement. The merger is expected to be completed in around mid September and the rights issue is expected to be completed during October 2025.
